Downstream processing of viral vectors and vaccines

Area of Science:

• Biotechnology
• Virology
• Medical Science

Background:

• Viral vectors (adenoviruses, adeno-associated viruses, retroviruses) are key for gene therapy delivery.
• Viral vaccines (rabies, influenza, hepatitis) are vital for controlling viral diseases and pandemics.
• Increasing safety demands from regulatory bodies (FDA, EMEA) necessitate enhanced production and purification.

Purpose of the Study:

• To highlight the evolving landscape of viral vector and vaccine production.
• To discuss the shift towards improved manufacturing and purification techniques.
• To address the impact of regulatory standards on the development of viral therapeutics.

Main Methods:

• Transition from traditional egg-based cultivation to mammalian cell culture systems for vaccine production.
• Adoption of advanced purification techniques, including tangential flow filtration and liquid chromatography.
• Comparison of new methods against classical techniques like sucrose gradient centrifugation.

Main Results:

• Mammalian cell culture offers an alternative to egg-based systems for viral vaccine manufacturing.
• Advanced purification methods provide higher efficiency and safety compared to older techniques.
• Technological advancements are enabling better control over viral vector and vaccine quality.

Conclusions:

• The field is moving towards more sophisticated and safer methods for producing viral vectors and vaccines.
• Regulatory pressures are a significant driver for innovation in biopharmaceutical manufacturing.
• Continued development in production and purification is essential for advancing gene therapy and vaccinology.